Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: Results From a Propensity Score–Matched Analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Registry
暂无分享,去创建一个
M. Pencina | L. Mauri | S. Bangalore | N. Kleiman | D. Cohen | S. Rao | Tal Regev-Beinart | D. Cohen
[1] Rio de la Plata Expert Panel. Antithrombotic Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes , 2012 .
[2] J. Ornato,et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST‐Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) , 2009, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[3] G. Stone,et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. , 2009, Journal of the American College of Cardiology.
[4] A. Kastrati,et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. , 2008, The New England journal of medicine.
[5] K. Kent,et al. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris. , 2008, The American journal of cardiology.
[6] G. Guyatt,et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.
[7] B. Gersh,et al. Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.
[8] A. Kastrati,et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. , 2008, Journal of the American College of Cardiology.
[9] J. Ornato,et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.
[10] William Wijns,et al. [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. , 2007, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.
[11] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[12] H. White,et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. , 2007, Journal of the American College of Cardiology.
[13] Adelaide,et al. Bivalirudin for patients with acute coronary syndromes. , 2006, The New England journal of medicine.
[14] S. Yusuf,et al. Adverse Impact of Bleeding on Prognosis in Patients With Acute Coronary Syndromes , 2006, Circulation.
[15] M. Gheorghiade,et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. , 2006, European heart journal.
[16] Joseph P Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[17] J. Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention) , 2006, Journal of the American College of Cardiology.
[18] David J Cohen,et al. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. , 2005, American heart journal.
[19] R. Califf,et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. , 2005, The American journal of cardiology.
[20] Antonio Colombo,et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. , 2005, European heart journal.
[21] F. Laduca,et al. Optimizing management of hirudin anticoagulation. , 2005, The journal of extra-corporeal technology.
[22] E. Topol,et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. , 2004, Journal of the American College of Cardiology.
[23] E. Topol,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.
[24] G. Levine,et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. , 2003, Journal of the American College of Cardiology.
[25] M. Nauck,et al. Methods for the monitoring of direct thrombin inhibitors. , 2002, Seminars in thrombosis and hemostasis.
[26] Carl J Pepine,et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.
[27] D. Rubin. Using Propensity Scores to Help Design Observational Studies: Application to the Tobacco Litigation , 2001, Health Services and Outcomes Research Methodology.
[28] E. Topol,et al. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. , 2001, American heart journal.
[29] David O. Williams,et al. ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .
[30] K A Eagle,et al. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.
[31] P D Cleary,et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. , 2001, Journal of clinical epidemiology.
[32] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[33] W. Gray,et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. , 2004, Thrombosis research.